Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.43 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12247403 | 0.89 | SIGMAR1 (0.43) | KDM1ASIGMAR1EBPTSHRTP53 | |
| SCHEMBL9067330 | 0.84 | KDM1A (0.53) | KDM1AMEN1KMT2ASIGMAR1EBP | |
| SCHEMBL20136589 | 0.82 | KDM1A (0.51) | KDM1AMEN1KMT2ASIGMAR1EBP | |
| SCHEMBL11742012 | 0.77 | ALDH1A1 (0.39) | KMT2AHTR2A | |
| SCHEMBL30128211 | 0.77 | ALDH1A1 (0.39) | KMT2AHTR2A | |
| SCHEMBL8589180 | 0.76 | CYP3A4 (0.51) | KDM1AKMT2ASIGMAR1TSHRCYP3A4 | |
| SCHEMBL6227623 | 0.75 | KDM1A (0.44) | KDM1AMEN1KMT2ASIGMAR1EBP | |
| SCHEMBL9583936 | 0.75 | KDM1A (0.51) | KDM1AMEN1KMT2ASIGMAR1TSHR | |
| SCHEMBL11472527 | 0.75 | KDM1A (0.44) | KDM1AMEN1KMT2ASIGMAR1TSHR | |
| SCHEMBL578812 | 0.75 | KDM1A (0.59) | KDM1AMEN1KMT2ASIGMAR1EBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2938341-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2938341-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| WO-2014106238-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FANG, QUN, KEVIN (US) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014106238-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FANG, QUN, KEVIN (US) | 2014-07-03 | — | — | WO | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-0360324-B1 | TRICYCLIC AROMATASE INHIBITORS | AKZO N.V. (NL) | 1992-11-11 | — | — | EP | disclosed |
| US-5019585-A | Tricyclic aromatase inhibitors | AKZO N.V. (NL) | 1991-05-28 | — | — | US | disclosed |
| EP-0360324-A1 | Tricyclic aromatase inhibitors | AKZO N.V. (NL) | 1990-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | KDM1A 2917/4885MEN1 709/4885KMT2A 1403/4885 |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | KDM1A 2831/4885MEN1 813/4885KMT2A 3252/4885 |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | GRIN2C, COMT, NLN | KDM1A 3995/4885MEN1 2159/4885KMT2A 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.